Scribe Therapeutics (NASDAQ:SCTX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Scribe Therapeutics (NASDAQ:SCTX) to a hold rating in a report issued on Saturday morning.

Scribe Therapeutics Price Performance

Shares of SCTX stock opened at $19.48 on Friday. Scribe Therapeutics has a 12-month low of $17.31 and a 12-month high of $25.49.

Insiders Place Their Bets

In other Scribe Therapeutics news, CFO David Parrot purchased 2,666 shares of the firm’s stock in a transaction dated Thursday, July 23rd. The stock was bought at an average price of $15.00 per share, with a total value of $39,990.00. Following the completion of the purchase, the chief financial officer owned 1,333 shares in the company, valued at $19,995. This trade represents a -200.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Behzad Aghazadeh purchased 2,383,333 shares of the stock in a transaction dated Friday, July 24th. The shares were acquired at an average cost of $15.15 per share, for a total transaction of $36,107,494.95. Following the completion of the acquisition, the director directly owned 3,080,983 shares of the company’s stock, valued at approximately $46,676,892.45. This trade represents a 341.62% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 3,727,237 shares of company stock worth $56,291,746.